Retatrutide

A single-chain peptide investigated as a triple GIP/GLP-1/glucagon receptor agonist in metabolic-regulation research.

Further reading: Retatrutide on The Peptide Guide — an independent Canadian reference with compound profiles and a reconstitution calculator. Educational only; nothing there is a statement about this product.

Research background

Retatrutide is an investigational single-chain peptide designed to act at three receptors at once — GIP, GLP-1 and glucagon. That triple-agonist design is what distinguishes it from the single- and dual-receptor compounds that preceded it in the same research class. Published work examines receptor binding and downstream signalling in metabolic-regulation models. Retatrutide is investigational: it is not approved by Health Canada or the FDA for any use, and its clinical trial programme belongs to the pharmaceutical developer running it. Nothing in that programme describes, or applies to, material supplied for laboratory research. Research Use Only. Not for human or veterinary use.

Supplied as a lyophilised powder for laboratory research use only. Any context described above refers to published preclinical or in-vitro research — not to human or veterinary use.